FDA Investigator Leigh Anne Myers

Leigh Anne Myers has conducted inspections on 147 sites in 15 countries as of 27 Jul 2005. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
147
Last Inspection Date:
27 Jul 2005
Investigator Role:
FDA Investigation Participant
Redica ID:
100000386
Countries of Inspections:
United Kingdom of Great Britain and Northern Ireland, United States of America, Mexico, Canada, Belgium, Italy, Sweden, Norway, Spain, Estonia, Netherlands, Greece, South Africa, Hungary, Taiwan
FDA Investigators that have inspected at least one site in common with Leigh Anne Myers:
Adam J Taylor, Adrian D Land, Alanna L Mussawwir Bias, Albert F Peacock, PhD, Amanda L Baskin, Andrace L Deyampert, Andrea D Swingle, Angel S Johnson, Ava M Bowman, Barbara A Rusin, Bei Y He, Benjamin J Smith, Bernard P Heidt, Betsy C Galliher, Bonnie L Menzel, Brandi N Mcgrady, Brandon L Mariner, Brian D Garthwaite, Brian P Hendrickson, Brittany M Lowe, Byungja E Marciante, Calvin K Cook, Catherine V Quinlan, CDR Kimberly Y Martin, Charles E Frelix, Charles I Ann, Charles L Zhou, Charles M Spyr, Cheron M Portee, Constantin Y Philopoulos, Corrine M Carter, Crystal M Young Lewis, Daniel J Gorski, David A Paterson, David L Duncan, Dawn C Olenjack, Debara R Reese, Debara Reese, Denise L Burosh, Dennis E Guilfoyle, PhD, Dennis R Downer, Dina A Tallman, Donald C Obenhuber, PhD, Dr. Abhijit Raha, PhD, Dr. Roy A Blay, PhD, Emest F Bizjak, Emily J Orban, Eric Zhu, Erma Zaimova, Etty Feller, Everard A Irish, Garrad R Poole, Hans T Meyers, Helen B Ricalde, Ifueko Osemwota, James A Lane, James N Rench, Jean Blackston Hill, Jeffrey A Sommers, Jeffrey D Meng, Jennifer A Kemp, Jennifer L Sheehan, Jorge F Christian, Joris Vanloco, Joseph A Piechocki, Joseph R Strelnik, Judith A Jankowski, Karen M Cooper, Karen M Montgomery (KMM), Kathleen B Swat, Kristina Nastovski, L'oreal D Fowlkes, L'oreal F Walker, Larry K Austin, Lauren Iacono Connors, PhD, LCDR Ismael Olvera, IV, Lesley Maep Lutao, Lewis K Antwi, Lisa M Bellows, Lisa P Oakes, Luella J Rossi, Lynda L Lanning, Maira P Brading, Marianne Allen, Matthew J Gretkierewicz, Meisha R Sampson, Meisha Waters, Melina Lrodriguez Upton, Mercy Oyugi, Michael Shanks, MS, Michael Y Philopoulos, Michele L Forster, PhD, Montgomery Montgomery, Karen M, Muna Algharibeh, Myra K Casey, Nailing Zhang, Nancy L Neiger, Natalie A Mickelsen, DVM, Neal D Singletary, PhD, Neali H Lucas, Nerizza B Guerin, Patricia A Birham, Patricia A Cochran, Patricia H Dlugosz, Patricia S Smith, Patrick B Cummings, Patsy J Domingo, Peter Kessler, PhD, Qiao Y Bobo, Rafeeq A Habeeb, Ralph A Erickson, Raymond T Oji, Rebecca E Dombrowski, Reginald Walker, Robert D Tollefsen, Robert J Ham, Robert M Barbosa, Sandra A Boyd, Sherri J Blessman, Sherri J Jackson, Sidney B Priesmeyer, Stephanie Mangigian, MS/OSH, RN, Susan F Laska, MS, Susan M North, Susan P Bruederle, Suyang Qin, Tara R Gooen, Thomas J Arista, Thuy T Nguyen, LCDR, Timothy C Schell, Tina M Pawlowski, Travis S Bradley, Vera M Anderson, Wayne E Seifert, William D Tingley, Yangmin Ning, Young M Yoon, Yumi J Hiramine

Leigh Anne Myers's Documents

Publish Date Document Type Title
February, 2003 FDA 483 Richard Bergeron, MD, PhD - Form 483, 2003-02-28
April, 2001 FDA 483 Indiana Lions Eye Bank, Inc. (dbA VisionFirst Indiana Lions Eye Bank) - Form 483, 2001-04-03
March, 2001 EIR Covance Bioanalytical Services, LLC - EIR, 2001-03-15
December, 2000 FDA 483 Elanco Clinton Laboratories - Form 483, 2000-12-08
June, 2002 FDA 483 Response Labcorp Drug Development Inc. - Form 483R, 2002-06-14
December, 2001 FDA 483 Dr. Ives Fradet - Form 483, 2001-12-14
January, 2001 FDA 483 Response Pfizer Inc - Form 483R, 2001-02-12
January, 2001 EIR Pfizer Inc - EIR, 2001-01-23
June, 2002 EIR Labcorp Drug Development Inc. - EIR, 2002-03-22
July, 2002 EIR Dr. Ting-Tsung Chang - EIR, 2002-07-26
March, 2004 FDA 483 McDougle, Christopher J., MD - Form 483, 2004-03-12
May, 2003 EIR Labcorp Drug Development Inc. - EIR, 2003-05-28
January, 2001 FDA 483 Pfizer Inc - Form 483, 2001-01-23
September, 2002 FDA 483 Labcorp Drug Development Inc. - Form 483, 2002-09-18
May, 2004 EIR Turik, Michael A. MD - EIR, 2004-05-05
February, 2003 FDA 483 Response Richard Bergeron, MD, PhD - Form 483R, 2003-02-28
January, 2002 EIR Lilly ICOS Llc - EIR, 2002-01-14
December, 2000 EIR Elanco Clinton Laboratories - EIR, 2000-12-08
September, 2002 FDA 483 Response Labcorp Drug Development Inc. - Form 483R, 2002-10-08
June, 2002 FDA 483 Labcorp Drug Development Inc. - Form 483, 2002-06-04
December, 2001 EIR Dr. Alvaro Morales - EIR, 2001-12-06
July, 2005 EIR Cook Inc. - EIR, 2005-07-07
June, 2002 FDA 483 Labcorp Drug Development Inc. - Form 483, 2002-03-22
June, 2002 EIR Labcorp Drug Development Inc. - EIR, 2002-05-30
February, 2003 EIR Richard Bergeron, MD, PhD - EIR, 2003-03-10
December, 2001 EIR Dr. Ives Fradet - EIR, 2001-12-14
May, 2004 EIR Eli Lilly and Company - EIR, 2004-05-21
June, 2002 FDA 483 Universal Reagents, Inc. - Form 483, 2002-06-03
December, 2000 FDA 483 Response Elanco Clinton Laboratories - Form 483R, 2000-12-20
September, 2002 EIR Labcorp Drug Development Inc. - EIR, 2002-09-18
June, 2002 FDA 483 Response Labcorp Drug Development Inc. - Form 483R, 2002-06-14

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more